Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Envafolimab + Endostar + AG in Advanced Pancreatic Cancer
NCT05298020Phase 2Unknown
- Sponsor
- The Affiliated Hospital of Xuzhou Medical University
- Start
- Apr 2022
- Primary completion
- Dec 2022
- Modality
- Nanobodies (VHH), Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of envafolimab in pancreatic cancer (PC), sponsored by The Affiliated Hospital of Xuzhou Medical University. Status: unknown.
02
Drugs
envafolimab
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT05298020.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05298020.